Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury

Audience: Gastroenterology, Nephrology, Pharmacy   [Posted 01/25/2013] ISSUE: Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca. In a double-blind, 3-year, placebo-controlled trial...
Source: Drugs.com - FDA MedWatch Alerts - Category: Drugs & Pharmacology Source Type: news